Compass Therapeutics
53 articles with Compass Therapeutics
-
Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/15/2023
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported fourth quarter and full year 2022 financial results.
-
Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference
2/2/2023
Compass Therapeutics, Inc. today announced that the Company will participate in the SVB Securities Global Biopharma Conference, which is taking place virtually on February 13 – 16, 2023.
-
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
1/19/2023
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the presentation of data from a Phase 2 study of CTX-009 in combination with paclitaxel in patients with biliary tract cancers (BTC).
-
Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer
1/6/2023
Compass Therapeutics, Inc. today announced that the first patient has been dosed in the Phase 2 U.S. study of CTX-009 in patients with metastatic colorectal cancer who are being treated in the third- and fourth-line setting.
-
Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21
12/15/2022
Compass Therapeutics, Inc. (Nasdaq: CMPX) today announced that updated results from the ongoing Phase 2 study of CTX-009 combined with paclitaxel in patients with biliary tract cancer (BTC) will be presented at a poster session of the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) taking place in San Francisco, CA January 19-21, 2023.
-
Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)
12/1/2022
Compass Therapeutics, Inc. today announced that the first patient has been dosed in the Phase 1b study of CTX-471 in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with advanced solid tumors.
-
Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
11/22/2022
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference, which is taking place at the Lotte New York Palace November 29 – December 1, 2022.
-
Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/9/2022
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter and year-to-date 2022 financial results and provided a corporate update.
-
Compass Therapeutics to Present at Upcoming Investment Conferences in November 2022
11/8/2022
Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, announced it will be presenting at the following investor conferences during the month of November 2022.
-
Compass Therapeutics Announces $80 Million Private Placement
11/2/2022
Compass Therapeutics, Inc announced that it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 25,000,000 shares of its common stock at an offering price of $3.21 per share through a private investment in public equity financing.
-
Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab)
10/11/2022
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada).
-
Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
9/9/2022
Compass Therapeutics, Inc. announced that the Company will participate in the 24th Annual H.C. Wainwright Global Investment Conference, which is taking place in New York City September 12 – 14, 2022.
-
Compass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
8/2/2022
Compass Therapeutics, Inc. today announced it will present at the 2022 Wedbush PacGrow Healthcare Conference that will take place virtually August 9 – 10, 2022.
-
Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/1/2022
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported second quarter and year-to-date 2022 financial results and provided a corporate update.
-
Compass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
5/31/2022
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will present at the 2022 Jefferies Global Healthcare Conference that will be held in New York City on Thursday, June 9, 2022, at 8:00 am ET.
-
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
5/23/2022
Compass Therapeutics, Inc. announced Thomas J. Schuetz, M.D., Ph.D., Co-founder and Chief Executive Officer, is presenting virtually at the 2022 H.C. Wainwright Global Investment Conference, occurring May 23-26th, 2022.
-
Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
5/9/2022
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2022 financial results.
-
Compass Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 11:20 a.m. PT
5/5/2022
Compass Therapeutics, Inc. announced Thomas J. Schuetz, M.D., Ph.D., Co-founder, and Chief Executive Officer is presenting at the Bank of America Securities 2022 Healthcare Conference to be held in-person in Las Vegas on May 12th, 2022, at 11:20am PT.
-
Compass and AstraZeneca have both provided updates to their clinical therapeutic programs focused on biliary tract cancers.
-
Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers
5/4/2022
Compass Therapeutics, Inc. today reported additional interim results from a Phase 2 study of CTX-009 in combination with paclitaxel in patients with biliary tract cancers (BTC). The data show that: